OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal

Immune modulation for cancer therapy

(2014) J Naidoo et al.   BRITISH JOURNAL OF CANCER

Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging

(2014) Michelle Farazi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Biochemical Signaling of PD-1 on T Cells and Its Functional Implications

(2014) Vassiliki A. Boussiotis et al.   CANCER JOURNAL

Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer

(2014) R D Harvey   CLINICAL PHARMACOLOGY & THERAPEUTICS

Orchestrating immune check-point blockade for cancer immunotherapy in combinations

(2014) Jose Luis Perez-Gracia et al.   CURRENT OPINION IN IMMUNOLOGY

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

(2014) Yannick Bulliard et al.   IMMUNOLOGY AND CELL BIOLOGY

Activation of NF- B1 by OX40 Contributes to Antigen-Driven T Cell Expansion and Survival

(2014) J. Song et al.   JOURNAL OF IMMUNOLOGY

IL-12 Is Required for Anti-OX40-Mediated CD4 T Cell Survival

(2014) C. E. Ruby et al.   JOURNAL OF IMMUNOLOGY

OX40-Enhanced Tumor Rejection and Effector T Cell Differentiation Decreases with Age

(2014) C. E. Ruby et al.   JOURNAL OF IMMUNOLOGY

Intratumoral CD4 + T Lymphodepletion Sensitizes Poorly Immunogenic Melanomas to Immunotherapy with an OX40 Agonist

(2014) Susumu Fujiwara et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer

(2014) Zhiqiang Guo et al.   PLoS One

Costimulatory TNFR family members in control of viral infection: Outstanding questions

(2014) Achire N. Mbanwi et al.   SEMINARS IN IMMUNOLOGY

The TNF family in T cell differentiation and function – Unanswered questions and future directions

(2014) Michael Croft   SEMINARS IN IMMUNOLOGY

Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored

(2014) Luis de la Cruz-Merino et al.   Frontiers in Immunology

Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8+ T cells

(2014) Michael J McNamara et al.   Journal for ImmunoTherapy of Cancer

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

(2014) David A Schaer et al.   Journal for ImmunoTherapy of Cancer

Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity

(2013) Elena Gianchecchi et al.   AUTOIMMUNITY REVIEWS

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

(2013) H. E. Kohrt et al.   BLOOD

Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer

(2013) J. Duraiswamy et al.   CANCER RESEARCH

OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

(2013) B. D. Curti et al.   CANCER RESEARCH

Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model

(2013) A. Morales-Kastresana et al.   CLINICAL CANCER RESEARCH

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment

(2013) Joel Crespo et al.   CURRENT OPINION IN IMMUNOLOGY

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

(2013) Aurélien Marabelle et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells

(2013) Erin E. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

(2013) Deborah A. Knight et al.   JOURNAL OF CLINICAL INVESTIGATION

CD8+ T Cell-Independent Tumor Regression Induced by Fc-OX40L and Therapeutic Vaccination in a Mouse Model of Glioma

(2013) K. A. Murphy et al.   JOURNAL OF IMMUNOLOGY

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

(2013) Margaret K. Callahan et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Strength of PD-1 signaling differentially affects T-cell effector functions

(2013) F. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TIM-3 Does Not Act as a Receptor for Galectin-9

(2013) Judith Leitner et al.   PLoS Pathogens

Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity

(2013) W. L. Redmond et al.   Cancer Immunology Research

Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells

(2013) Ashley Mentlik James et al.   Frontiers in Immunology

Role of the PD-1 Pathway in the Immune Response

(2012) L. V. Riella et al.   AMERICAN JOURNAL OF TRANSPLANTATION

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

(2012) N. Vey et al.   BLOOD

Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40

(2012) Y. Yang et al.   BLOOD

Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells

(2012) E. F. Tewalt et al.   BLOOD

Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas

(2012) Muhammad Baghdadi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape

(2012) Gang Zhou et al.   Clinical & Developmental Immunology

An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

(2012) K. A. Murphy et al.   CLINICAL CANCER RESEARCH

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

(2012) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

NK cell MHC class I specific receptors (KIR): from biology to clinical intervention

(2012) Ariane Thielens et al.   CURRENT OPINION IN IMMUNOLOGY

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy

(2012) Michael J. Gough et al.   IMMUNOLOGY

Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients

(2012) Fu-Jun Li et al.   IMMUNOLOGY LETTERS

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of tumoricidal function in CD4+T cells is associated with concomitant memory and terminally differentiated phenotype

(2012) Daniel Hirschhorn-Cymerman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression

(2012) William L. Redmond et al.   PLoS One

Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses

(2012) Thomas Höfer et al.   Frontiers in Immunology

Ligand specificity of Killer cell Immunoglobulin-like Receptors: a brief history of KIR

(2012) Jeroen van Bergen et al.   Frontiers in Immunology

Combinatorial Immunotherapy

(2012) Meghan E. Turnis et al.   OncoImmunology

Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies

(2012) Inge Verbrugge et al.   OncoImmunology

PD-1 and BTLA and CD8+T-cell “exhaustion” in cancer

(2012) Cara Haymaker et al.   OncoImmunology

The confluence of radiotherapy and immunotherapy

(2012) Byron Burnette et al.   Frontiers in Oncology

Follicular Helper CD4 T Cells (TFH)

(2011) Shane Crotty   Annual Review of Immunology

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma

(2011) J. Qian et al.   BLOOD

Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses

(2011) Shannon E. Smith et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors

(2011) S. F. Ngiow et al.   CANCER RESEARCH

CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

(2011) J. Fourcade et al.   CANCER RESEARCH

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma

(2011) X. Frigola et al.   CLINICAL CANCER RESEARCH

Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms

(2011) Mikayel Mkrtichyan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells

(2011) Alessia Burocchi et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations

(2011) Kerry S. Campbell et al.   IMMUNOLOGY

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

(2011) Jacalyn Rosenblatt et al.   JOURNAL OF IMMUNOTHERAPY

Active Immunotherapy Combined With Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone Mice

(2011) Marcio O Lasaro et al.   MOLECULAR THERAPY

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

(2010) Michael Croft   Annual Review of Immunology

A Therapeutic OX40 Agonist Dynamically Alters Dendritic, Endothelial, and T Cell Subsets within the Established Tumor Microenvironment

(2010) A. D. Pardee et al.   CANCER RESEARCH

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

(2010) Yan Zhang et al.   Cellular & Molecular Immunology

Putting the brakes on BTLA in T cell–mediated cancer immunotherapy

(2010) Chrystal M. Paulos et al.   JOURNAL OF CLINICAL INVESTIGATION

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

(2010) Laurent Derré et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization

(2010) Q. Zhou et al.   JOURNAL OF IMMUNOLOGY

Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules

(2010) K. Takeda et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: Lack of High Affinity Competition for Peptide in Polyclonal CD4+ Responses Unmasks IL-4 Production

(2010) J. D. Milner et al.   JOURNAL OF IMMUNOLOGY

Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice

(2010) Michael J. Gough et al.   JOURNAL OF IMMUNOTHERAPY

Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

(2010) Sara M. Mangsbo et al.   JOURNAL OF IMMUNOTHERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance

(2010) V. A. Pedicord et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

(2010) Junko Matsuzaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications

(2010) Anna Maria Di Giacomo et al.   SEMINARS IN ONCOLOGY

Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade

(2010) Jeffrey Weber   SEMINARS IN ONCOLOGY

Signaling Through OX40 Enhances Antitumor Immunity

(2010) Shawn M. Jensen et al.   SEMINARS IN ONCOLOGY

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors

(2009) B. Li et al.   CLINICAL CANCER RESEARCH

Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo

(2009) William L. Redmond et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Follicular Helper T Cells: Lineage and Location

(2009) Nicolas Fazilleau et al.   IMMUNITY

Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections

(2009) Tsvetelina Pentcheva-Hoang et al.   IMMUNOLOGICAL REVIEWS

The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation

(2009) Guifang Cai et al.   IMMUNOLOGICAL REVIEWS

Early commitment of naïve human CD4+ T cells to the T follicular helper (TFH ) cell lineage is induced by IL-12

(2009) Cindy S Ma et al.   IMMUNOLOGY AND CELL BIOLOGY

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells

(2009) Wenshi Wang et al.   INTERNATIONAL IMMUNOLOGY

Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model

(2009) Miura   INTERNATIONAL JOURNAL OF ONCOLOGY

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

(2009) Daniel Hirschhorn-Cymerman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells

(2009) J. F. Grosso et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right

(2009) C. E. Ruby et al.   JOURNAL OF IMMUNOLOGY

Fc-mOX40L Fusion Protein Produces Complete Remission and Enhanced Survival in 2 Murine Tumor Models

(2009) Rebecca E. Sadun et al.   JOURNAL OF IMMUNOTHERAPY

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

(2008) R. Houot et al.   BLOOD

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

(2008) B. Kavanagh et al.   BLOOD

OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor

(2008) M. J. Gough et al.   CANCER RESEARCH

Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer

(2008) Hiroshi Yokouchi et al.   CANCER SCIENCE

Assembling OX40 Aptamers on a Molecular Scaffold to Create a Receptor-Activating Aptamer

(2008) Claudia M. Dollins et al.   CHEMISTRY & BIOLOGY

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies

(2008) Juliet C. Gray et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

(2008) Silvia Piconese et al.   JOURNAL OF EXPERIMENTAL MEDICINE